Newsletter
Every new paper in this field, in your inbox.
In an analysis of 1887 patients with gastro-oesophageal cancer, only those with a partial response to neoadjuvant FLOT chemotherapy showed significant improvements in disease-free survival (DFS) and overall survival (OS) when treated with adjuvant FLOT. Patients categorized as minimal responders or complete responders did not…
A prospective study involving 123 esophageal squamous cell carcinoma patients demonstrates that post-treatment circulating tumor DNA (ctDNA) and PET/CT metrics can effectively differentiate those with pathological complete response (pCR) from non-pCR patients. The model, integrating ctDNA concentration and mean standardized uptake value (SUVmean), achieved areas…
A study reveals that minimally invasive esophagectomy (MIE) and robotic-assisted minimally invasive esophagectomy (RAMIE) significantly reduce postoperative pain and pulmonary infections compared to traditional surgery. Both techniques, requiring specialized training, demonstrate improved short-term outcomes and comparable oncological results to open esophagectomy. The robotic-assisted approach offers…
Oligometastatic patients with esophageal, gastro-esophageal junction, and gastric cancers experience improved outcomes with aggressive multimodal therapies. Research indicates that combining systemic therapy with surgical resection of primary tumors and metastases enhances prognosis. Notably, patients with oligometastatic cancer at the esophago-gastric junction showed potential for curative…
Recent advancements in immunotherapy provide new treatment avenues for advanced esophageal cancer, particularly for squamous cell carcinoma and esophagogastric adenocarcinoma. Immune checkpoint inhibitors, such as nivolumab and pembrolizumab, are now approved in various treatment settings, including adjuvant therapy for patients post-surgery and first-line treatments combined…
A multicenter trial revealed that spray coagulation mode endoscopic submucosal dissection (scm-esd) significantly improved completion rates for treating early gastric neoplasms without the use of hemostatic forceps, achieving 83.1% versus 13.8% for conventional forced coagulation mode (fcm-esd). Procedure time and adverse event rates were comparable…
Recent findings reveal that immune checkpoint inhibitors (ICIs) significantly improve treatment outcomes for advanced gastric adenocarcinoma (GAC), especially in patients with specific molecular subtypes such as MSI-H and HER2-positive. Combining ICIs with chemotherapy or targeted therapies enhances efficacy, despite the risk of immune-related adverse events…
Higher stages of the OLGA and OLGIM staging systems significantly correlate with an elevated risk of developing high-grade dysplasia (HGD) and gastric cancer (GC). A systematic review and meta-analysis of eight prospective cohort studies found that moving from OLGA/OLGIM categories 0-II to III-IV notably increases…
A nutrition-based nomogram has been developed to predict the risk of intra-abdominal infection (IAI) after D2 radical gastrectomy for gastric cancer. An analysis of 404 patients identified key indicators, including the NRS2002 score, fasting blood glucose, and multi-visceral resection, associating them with IAI risk. The…
Significant preoperative amino acid elevations were found in gastric cancer patients. Post-surgery, many amino acids decreased but were partially restored with nutritional intervention, with some levels surpassing preoperative values. However, methionine and glutamine remained lower than in healthy individuals. Correlations were identified between specific amino…
